Catharina Missailidis1, Ujjwal Neogi1,2, Peter Stenvinkel3, Marius Trøseid4,5,6, Piotr Nowak7, Peter Bergman1. 1. Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge. 2. Science for Life Laboratory, Division of Proteomics and Nanobiotechnology, KTH Royal Institute of Technology, Solna. 3. Division of Renal Medicine, Department of Clinical Science Intervention and Technology, Karolinska University Hospital Huddinge, Stockholm, Sweden. 4. Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet. 5. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo. 6. Section of Clinical Immunology and Infectious diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway. 7. Department of Medicine Huddinge, Unit of Infectious Disease, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Abstract
OBJECTIVE: HIV-1-infection infers an increased cardiovascular risk where gut dysbiosis and microbial translocation may contribute. We assessed TMAO, a microbial metabolite with atherosclerotic properties, in plasma of HIV-1-infected individuals at different clinical stages in relation to inflammatory markers, cardiovascular events and gut microbiota. METHODS: Primary HIV-1-infected (n = 17) and chronic HIV-1-infected individuals (n = 22) were sampled before and after ART-initiation. In the chronic HIV-1-cohort, repeated faecal samples were analysed by 16SrRNA gene sequencing. HIV-1-infected individuals on longstanding ART (n = 101) and healthy HIV-1-negative individuals (n = 60), served as controls. TMAO and markers of immune activation were analysed by LC/MS/MS and immune assays, respectively. RESULTS: TMAO levels were lower in untreated HIV-1-infected individuals, increased significantly after ART-initiation (P = 0.040 and P < 0.001) but remained similar to healthy controls. TMAO levels were not affected by ART, immune status or degree of systemic inflammation. Higher TMAO in HIV-1-infected individuals on longstanding ART was not significantly associated with cardiovascular risk (P = 0.38). Additionally, TMAO levels correlated inversely with Bacteroidetes (Rho: -0.62, P = 0.002), and positively with Firmicutes (Rho: 0.65, P = 0.001) but held no correlation to TMA-producing genera. Notably gut dysbiosis at follow-up was more pronounced in patients without increase in TMAO levels after ART characterized by loss of Bacteroidetes (P = 0.023) and significantly elevated LPS levels (P = 0.01). CONCLUSION: Our data does not support that TMAO is a significant link between gut dysbiosis and inflammation in HIV-1-infection. We propose that HIV-1, microbial composition and ART disparately confound TMAO levels, thus limiting its role as a cardiovascular risk marker in HIV-1-infected individuals.
OBJECTIVE:HIV-1-infection infers an increased cardiovascular risk where gut dysbiosis and microbial translocation may contribute. We assessed TMAO, a microbial metabolite with atherosclerotic properties, in plasma of HIV-1-infected individuals at different clinical stages in relation to inflammatory markers, cardiovascular events and gut microbiota. METHODS: Primary HIV-1-infected (n = 17) and chronic HIV-1-infected individuals (n = 22) were sampled before and after ART-initiation. In the chronic HIV-1-cohort, repeated faecal samples were analysed by 16SrRNA gene sequencing. HIV-1-infected individuals on longstanding ART (n = 101) and healthy HIV-1-negative individuals (n = 60), served as controls. TMAO and markers of immune activation were analysed by LC/MS/MS and immune assays, respectively. RESULTS:TMAO levels were lower in untreated HIV-1-infected individuals, increased significantly after ART-initiation (P = 0.040 and P < 0.001) but remained similar to healthy controls. TMAO levels were not affected by ART, immune status or degree of systemic inflammation. Higher TMAO in HIV-1-infected individuals on longstanding ART was not significantly associated with cardiovascular risk (P = 0.38). Additionally, TMAO levels correlated inversely with Bacteroidetes (Rho: -0.62, P = 0.002), and positively with Firmicutes (Rho: 0.65, P = 0.001) but held no correlation to TMA-producing genera. Notably gut dysbiosis at follow-up was more pronounced in patients without increase in TMAO levels after ART characterized by loss of Bacteroidetes (P = 0.023) and significantly elevated LPS levels (P = 0.01). CONCLUSION: Our data does not support that TMAO is a significant link between gut dysbiosis and inflammation in HIV-1-infection. We propose that HIV-1, microbial composition and ART disparately confound TMAO levels, thus limiting its role as a cardiovascular risk marker in HIV-1-infected individuals.
Authors: Ana F Diallo; Mark B Lockwood; Katherine A Maki; Alexis T Franks; Abhrarup Roy; Rosario Jaime-Lara; Paule V Joseph; Wendy A Henderson; Seon Yoon Chung; Jacqueline McGrath; Stefan J Green; Anne M Fink Journal: Biol Res Nurs Date: 2020-07-29 Impact factor: 2.522
Authors: Nicholas Rhoades; Norma Mendoza; Allen Jankeel; Suhas Sureshchandra; Alexander D Alvarez; Brianna Doratt; Omeid Heidari; Rod Hagan; Brandon Brown; Steven Scheibel; Theodore Marbley; Jeff Taylor; Ilhem Messaoudi Journal: Front Immunol Date: 2019-03-12 Impact factor: 7.561
Authors: Dana Gabuzda; Beth D Jamieson; Ronald G Collman; Michael M Lederman; Tricia H Burdo; Steven G Deeks; Dirk P Dittmer; Howard S Fox; Nicholas T Funderburg; Savita G Pahwa; Ivona Pandrea; Cara C Wilson; Peter W Hunt Journal: Pathog Immun Date: 2020-06-17
Authors: Magnhild E Macpherson; Johannes R Hov; Thor Ueland; Tuva B Dahl; Martin Kummen; Kari Otterdal; Kristian Holm; Rolf K Berge; Tom E Mollnes; Marius Trøseid; Bente Halvorsen; Pål Aukrust; Børre Fevang; Silje F Jørgensen Journal: Front Immunol Date: 2020-09-16 Impact factor: 7.561